CARLYLE GROUP INC/THE

How Carlyle’s insider sale by David M. Rubenstein could impact share price, governance, and tax strategy – a deep dive into the Rule 144 and Form 4 filings.

David M. Rubenstein’s insider sale of 400 000 Carlyle shares on Sept 11, 2026 signals strategic capital restructuring and ESG‑aligned generosity, offering investors insight into Carlyle’s governance and future growth plans.

Explore Carlyle’s unaudited Q2 2026 results—solid assets, low debt, rising EPS—offering a clear snapshot for investors seeking stability and growth insight.

Discover how Carlyle’s latest update showcases disciplined growth, robust risk‑management, and ESG‑focused strategy to drive steady returns in today’s volatile market.

Inside the Carlyle Group: Executives buy shares, showing confidence and stable ownership amid 2026 market swings.

Uncover how Carlyle’s new board, earnings shifts, and tech promises hide real risks and hidden conflicts—why the firm’s “stable growth” narrative may mask deeper financial and human‑impact concerns.

Oncolytic virus cancer therapies are booming—key regulatory wins, rising prices, and new combos with checkpoints open a $3.5 B market, but safety, manufacturing, and payer hurdles loom.

Uncover how Carlyle’s Q4 2026 results reveal a 24% income jump, AI‑powered data services, and global expansion—insights for investors eyeing alternative asset growth.

Explore The Carlyle Group’s latest 13F‑HR filing: $10 B in diversified public‑equity holdings, clear governance, and sector‑specific alpha insights for investors.

Learn how Carlyle’s sale of Copia Power to EQT boosts AI‑infrastructure scale, diversifies revenue, and mitigates energy volatility for U.S. data‑center leaders.